5.27
+0.13(+2.53%)
Currency In USD
Address
499 Illinois Street
San Francisco, CA 94158
United States of America
Phone
415 906 4324
Website
Sector
Healthcare
Industry
Biotechnology
Employees
408
First IPO Date
October 11, 2019
| Name | Title | Pay | Year Born |
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer & Director | 4.79M | 1969 |
| Mr. Jason O'Byrne M.B.A. | Executive Vice President & Chief Financial Officer | 280,492 | 1969 |
| Dr. Mark D. Eisner M.D., M.P.H. | Executive Vice President & Chief Medical Officer | 978,420 | 1966 |
| Ms. Vanina de Verneuil J.D. | Executive Vice President, General Counsel & Corporate Secretary | 1.1M | 1979 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | 0 | N/A |
| Dr. Maninder Hora Ph.D. | Executive Vice President & Chief Technical Operations Officer | 0 | 1954 |
| Mr. Toby Medaris | Senior Vice President of Human Resources | 0 | N/A |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | 0 | 1947 |
| Mr. Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer | 0 | 1974 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President & Chief Scientific Officer | 0 | N/A |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.